title: Probing the intracellular redox status of tumors with magnetic resonance imaging and redox-sensitive contrast agents.
abstract: Nitroxide radicals are paramagnetic contrast agents, used in magnetic resonance imaging (MRI), that also exert antioxidant effects. Participating in cellular redox reactions, they lose their ability to provide contrast as a function of time after administration. In this study, the rate of contrast loss was correlated to the reducing power of the tissue or the "redox status." The preferential reduction of nitroxides in tumors compared with normal tissue was observed by MRI. The influence of the structure of the nitroxide on the reduction rate was investigated by MRI using two cell-permeable nitroxides, 4-hydroxy-2,2,6,6,-tetramethyl-1-piperidynyloxyl (Tempol) and 3-carbamoyl-2,2,5,5-tetramethylpyrrolidine-1-oxyl (3CP), and one cell-impermeable nitroxide, 3-carboxy-2,2,5,5,5-tetramethylpyrrolidine-1-oxyl (3CxP). Pharmacokinetic images of these nitroxides in normal tissue, tumor, kidney, and artery regions in mice were simultaneously obtained using MRI. The decay of Tempol and 3CP in tumor tissue was significantly faster than in normal tissue. No significant change in the total nitroxide (oxidized + reduced forms) was noted from tissue extracts, suggesting that the loss in contrast as a function of time is a result of intracellular bioreduction. However, in the case of 3CxP (membrane impermeable), there was no difference in the reduction rates between normal and tumor tissue. The time course of T(1) enhancement by 3CxP and the total amount of 3CxP (oxidized + reduced) in the femoral region showed similar pharmacokinetics. These results show that the differential bioreduction of cell-permeable nitroxides in tumor and normal tissue is supported by intracellular processes and the reduction rates are a means by which the intracellular redox status can be assessed noninvasively.
authors.affiliation: Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.
authors.forename: Fuminori
authors.initials: F
authors.lastname: Hyodo
authors.forename: Ken-Ichiro
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Atsuko
authors.initials: A
authors.lastname: Matsumoto
authors.forename: James B
authors.initials: JB
authors.lastname: Mitchell
authors.forename: Murali C
authors.initials: MC
authors.lastname: Krishna
mesh_terms: D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000378:metabolism*; D003287:Contrast Media / Q000737:chemistry / Q000493:pharmacokinetics*; D003497:Cyclic N-Oxides / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics*; D005260:Female; D005609:Free Radicals / Q000737:chemistry / Q000378:metabolism; D008279:Magnetic Resonance Imaging / Q000379:methods; D051379:Mice; D008809:Mice, Inbred C3H; D009374:Neoplasms, Experimental / Q000737:chemistry / Q000378:metabolism*; D009589:Nitrogen Oxides / Q000737:chemistry / Q000378:metabolism*; D010084:Oxidation-Reduction; D011759:Pyrrolidines / Q000737:chemistry / Q000493:pharmacokinetics*; D013113:Spin Labels; D013329:Structure-Activity Relationship
chemical_list: D003287:Contrast Media; D003497:Cyclic N-Oxides; D005609:Free Radicals; D009589:Nitrogen Oxides; D011759:Pyrrolidines; D013113:Spin Labels; C077426:3-carbamoyl-2,2,5,5-tetramethyl-1-pyrrolidinyl-N-oxyl; C001803:tempol